Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Feb;71(2):354–356. doi: 10.1038/bjc.1995.71

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.

G Scambia 1, U Testa 1, P Benedetti Panici 1, E Foti 1, R Martucci 1, A Gadducci 1, A Perillo 1, V Facchini 1, C Peschle 1, S Mancuso 1
PMCID: PMC2033591  PMID: 7841052

Abstract

High levels of IL-6 were found in 50% of 114 patients with primary ovarian cancer. IL-6 sensitivity was lower than that of CA 125, and the combination of both assays did not increase the sensitivity of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate analysis revealed that IL-6 positivity has an independent value.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benedetti Panici P., Greggi S., Scambia G., Baiocchi G., Lomonaco M., Conti G., Mancuso S. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Int J Gynecol Cancer. 1993 Jan;3(1):44–53. doi: 10.1046/j.1525-1438.1993.03010044.x. [DOI] [PubMed] [Google Scholar]
  2. Berek J. S., Chung C., Kaldi K., Watson J. M., Knox R. M., Martínez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991 Apr;164(4):1038–1043. doi: 10.1016/0002-9378(91)90582-c. [DOI] [PubMed] [Google Scholar]
  3. Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun 15;52(12):3317–3322. [PubMed] [Google Scholar]
  4. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992 Apr 1;148(7):2175–2180. [PubMed] [Google Scholar]
  5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  6. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989 Jul 3;250(2):607–610. doi: 10.1016/0014-5793(89)80805-1. [DOI] [PubMed] [Google Scholar]
  7. Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092–3096. doi: 10.1073/pnas.87.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Okada M., Kitahara M., Kishimoto S., Matsuda T., Hirano T., Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988 Sep 1;141(5):1543–1549. [PubMed] [Google Scholar]
  9. Scambia G., Benedetti Panici P., Perrone L., Sonsini C., Giannelli S., Gallo A., Natali P. G., Mancuso S. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies. Br J Cancer. 1990 Jul;62(1):147–151. doi: 10.1038/bjc.1990.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Scambia G., Testa U., Panici P. B., Martucci R., Foti E., Petrini M., Amoroso M., Masciullo V., Peschle C., Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer. 1994 May 1;57(3):318–323. doi: 10.1002/ijc.2910570305. [DOI] [PubMed] [Google Scholar]
  11. Tamm I., Cardinale I., Krueger J., Murphy J. S., May L. T., Sehgal P. B. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med. 1989 Nov 1;170(5):1649–1669. doi: 10.1084/jem.170.5.1649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tanner J., Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest. 1991 Jul;88(1):239–247. doi: 10.1172/JCI115283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Van Meir E., Sawamura Y., Diserens A. C., Hamou M. F., de Tribolet N. Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 1990 Oct 15;50(20):6683–6688. [PubMed] [Google Scholar]
  14. Watson J. M., Berek J. S., Martínez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol. 1993 Apr;49(1):8–15. doi: 10.1006/gyno.1993.1077. [DOI] [PubMed] [Google Scholar]
  15. Watson J. M., Sensintaffar J. L., Berek J. S., Martínez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990 Nov 1;50(21):6959–6965. [PubMed] [Google Scholar]
  16. Wu S., Rodabaugh K., Martinez-Maza O., Watson J. M., Silberstein D. S., Boyer C. M., Peters W. P., Weinberg J. B., Berek J. S., Bast R. C., Jr Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol. 1992 Mar;166(3):997–1007. doi: 10.1016/0002-9378(92)91379-o. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES